US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AgomAb Therapeutics

10.85

-1.0200-8.59%

Post-market: 10.850.00000.00%16:12 EDT

Volume:67.76K

Turnover:745.75K

Market Cap:528.79M

PE:0.00

High:12.00

Open:12.00

Low:10.51

Close:11.87

52wk High:17.45

52wk Low:10.50

Shares:48.74M

Float Shares:12.50M

Volume Ratio:0.34

T/O Rate:0.54%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3,391.5288

EPS(LYR):-2,395.7345

ROE:--

ROA:--

PB:-3.00

PE(LYR):0.00

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Agomab Therapeutics receives U.S. Patent No. 12,577,230 for AGMB-447; IP protection extends through at least 2041

Agomab Receives U.S. Patent for Agmb-447, Its Inhaled Lung-Restricted Small Molecule Inhibitor of Alk5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

THOMSON REUTERS

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Agomab Therapeutics NV Director David R Epstein Files Initial Beneficial Ownership Statement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AGMB"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":10.85,"timestamp":1774641600000,"preClose":11.87,"halted":0,"volume":67757,"hourTrading":{"tag":"盘后","latestPrice":10.85,"preClose":10.85,"latestTime":"16:12 EDT","volume":10,"amount":108.4,"timestamp":1774642337817,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.08593091828138161,"floatShares":12500000,"shares":48736779,"eps":-3391.5288,"marketStatus":"Market Closed","change":-1.02,"latestTime":"03-27 16:00:00 EDT","open":12,"high":12,"low":10.51,"amount":745754.2202,"amplitude":0.125527,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3391.5288,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":11.87,"postHourTrading":{"tag":"盘后","latestPrice":10.85,"preClose":10.85,"latestTime":"16:12 EDT","volume":10,"amount":108.4,"timestamp":1774642337817,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.3392113890043081},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":12500000,"roa":"--","roe":"--","lyrEps":-2395.734548,"volumeRatio":0.3392113890043081,"shares":48736779,"dividePrice":0,"high":12,"amplitude":0.125527,"preClose":11.87,"low":10.51,"week52Low":10.5,"pbRate":"-3.00","week52High":17.4528,"institutionHeld":0,"latestPrice":10.85,"eps":-3391.5288,"divideRate":0,"volume":67757,"delay":0,"ttmEps":-3391.5288,"open":12,"prevYearClose":16,"prevWeekClose":12.19,"prevMonthClose":16.02,"prevQuarterClose":16,"fiveDayClose":12.19,"twentyDayClose":16.02,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1773892800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-03-27","current":-0.003199,"percent":0.970588,"low":-14.725744,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"high":-10.600815,"avg":-13.107825,"sd":1.105762,"marketCap":578505566},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566}],"updateTime":1774761603526},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622085155","title":"Agomab Therapeutics receives U.S. Patent No. 12,577,230 for AGMB-447; IP protection extends through at least 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2622085155","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622085155?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:01","pubTimestamp":1774522892,"startTime":"0","endTime":"0","summary":"Agomab said the USPTO granted U.S. Patent No. 12,577,230 covering the composition of matter of AGMB-447.AGMB-447 is an investigational inhaled lung-restricted small molecule inhibitor of ALK5  in a Phase 1b study for idiopathic pulmonary fibrosis.The company said the patent provides U.S. IP protection through at least 2041, excluding potential patent term extensions.CEO Tim Knotnerus said Agomab expects results from the idiopathic pulmonary fibrosis patient cohort of the Phase 1b study later this year.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL2yYlHy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B3QW5Z07.USD","BK4585","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","NDAQ","AGMB","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","BK4112","SG9999014039.USD","BK4007","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD","LU2210149790.SGD","LU0314104364.USD","LU2210150020.SGD","IE00BN0W2T93.GBP"],"gpt_icon":0},{"id":"2622212859","title":"Agomab Receives U.S. Patent for Agmb-447, Its Inhaled Lung-Restricted Small Molecule Inhibitor of Alk5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2622212859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622212859?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA6BRHW8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"gpt_icon":0},{"id":"2622851262","title":"Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851262","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851262?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":"Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3262841/0/en/Agomab-Receives-U-S-Patent-for-AGMB-447-its-Inhaled-Lung-restricted-Small-Molecule-Inhibitor-of-ALK5-in-Development-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IP","AGMB","LU1481600234.SGD","LU1169590202.USD","LU2463526074.USD","BK4136","LU1169589451.USD","LU1481599808.USD","BK4588","BK4585","LU1487256676.USD","IE00B3T34201.USD","BK4007"],"gpt_icon":0},{"id":"2620473264","title":"Agomab Therapeutics NV Director David R Epstein Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620473264","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620473264?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:03","pubTimestamp":1773864192,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reported an initial statement of beneficial ownership for director David Epstein. Epstein disclosed stock options to buy 770,671 common shares at an exercise price of USD 2.81. He also reported stock options to buy 217,295 common shares at an exercise price of USD 5.26. In addition, Epstein reported stock options to buy 38,843 common shares at an exercise price of USD 14.26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL2nntt4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"gpt_icon":0}],"pageSize":4,"totalPage":8,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AGMB\",params:#limit:6,delay:false,,,undefined,":[]}}